Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Probi AB (publ)    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Probi publ : Presentation of Probi's Q2 report 2020 and new financial targets

share with twitter share with LinkedIn share with facebook
07/14/2020 | 02:31am EDT

Probi's report for the second quarter 2020 and the new financial targets will be published on Friday, 17 July at 8.00 a.m. CET.

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com (http://www.probi.se) or https://tv.streamfabriken.com/probi-q2-2020

The presentation can also be followed via a telephone conference on the following telephone number:
Sweden: + 46 8 50 55 83 59
UK: +44 33 33 00 92 69
US: + 1 83 35 26 83 96

After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast.

An on-demand version of the presentation will be available at the address given above following the presentation.

FOR FURTHER INFORMATION, CONTACT:
Henrik Lundkvist, CFO, Probi, tel +46 46 286 89 41, e-post: henrik.lundkvist@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. Probi's vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2019, Probi had net sales of MSEK 626. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi had about 4,000 shareholders on December 31, 2019. Read more at www.probi.com.

https://news.cision.com/probi/r/presentation-of-probi-s-q2-report-2020-and-new-financial-targets,c3153395

https://mb.cision.com/Main/1556/3153395/1278655.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) -1.30% 342.5 Delayed Quote.54.28%
SYMRISE AG -0.42% 117.75 Delayed Quote.25.53%
share with twitter share with LinkedIn share with facebook
All news about PROBI AB (PUBL)
08/27PROBI : New clinical results on stress from Probi and their probiotic strain L. ..
AQ
07/17Q2 2020 : Probi raises long-term financial targets
AQ
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
PU
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
AQ
07/02PROBI PUBL : and Örebro University to collaborate on research into exploration o..
AQ
05/14PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
AQ
05/14PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/13PROBI PUBL : ´s Annual General Meeting 2020
PU
05/13PROBI PUBL : Annual General Meeting 2020
AQ
04/24Q1 2020 : A solid start to the year
AQ
More news
Financials
Sales 2020 671 M 73,4 M 73,4 M
Net income 2020 92,0 M 10,1 M 10,1 M
Net cash 2020 284 M 31,1 M 31,1 M
P/E ratio 2020 41,5x
Yield 2020 0,45%
Capitalization 3 902 M 427 M 427 M
EV / Sales 2020 5,40x
EV / Sales 2021 4,88x
Nbr of Employees -
Free-Float 38,9%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 420,00 SEK
Last Close Price 342,50 SEK
Spread / Highest target 22,6%
Spread / Average Target 22,6%
Spread / Lowest Target 22,6%
EPS Revisions
Managers
NameTitle
Tom Juhani Rönnlund Chief Executive Officer
Jean-Yves Parisot Chairman
Andy McShea Vice President-Operations
Henrik Lundkvist Chief Financial Officer
Niklas Brandt Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)54.28%427
BY-HEALTH CO., LTD.26.76%4 785
BALCHEM CORPORATION-5.88%3 094
THE SIMPLY GOOD FOODS COMPANY-23.72%2 076
MEDIFAST, INC.50.48%1 931
JAMIESON WELLNESS INC.55.88%1 187